Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Silence Therapeutics (SLN) over the last 4 years, with Jun 2025 value amounting to $1,000.

  • Silence Therapeutics' Cash from Financing Activities fell 99.92% to $1,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $7.9 million, marking a year-over-year decrease of 95.12%. This contributed to the annual value of $142.1 million for FY2024, which is 344.90% up from last year.
  • Per Silence Therapeutics' latest filing, its Cash from Financing Activities stood at $1,000 for Q2 2025, which was down 92.86% from $14,000 recorded in Q1 2025.
  • Silence Therapeutics' Cash from Financing Activities' 5-year high stood at $133.0 million during Q1 2024, with a 5-year trough of -$98,000 in Q4 2024.
  • In the last 3 years, Silence Therapeutics' Cash from Financing Activities had a median value of $2.6 million in 2023 and averaged $17.4 million.
  • Over the last 5 years, Silence Therapeutics' Cash from Financing Activities had its largest YoY gain of 575,876.73% in 2024, and its largest YoY loss of 100.80% in 2024.
  • Silence Therapeutics' Cash from Financing Activities (Quarterly) stood at $585,898 in 2021, then surged by 8,562.23% to $51,609 in 2022, then soared by 23,756.82% to $12.3 million in 2023, then plummeted by 100.80% to -$98,000 in 2024, then slumped by 99.92% to $1,000 in 2025.
  • Its last three reported values are $1,000 in Q2 2025, $14,000 for Q1 2025, and -$98,000 during Q4 2024.